Literature DB >> 26818890

Discontinuing benzodiazepines: best practices.

G Guaiana1, C Barbui2.   

Abstract

In July 2015, the Canadian Agency for Drugs and Technologies in Health (CADTH) released a Rapid Response report summary, with a critical appraisal, on discontinuation strategies for patients with long-term benzodiazepines (BDZ) use. The CADTH document is a review of the literature. It includes studies whose intervention is BDZ discontinuation. Also, clinical guidelines, systematic reviews and meta-analyses are included. What emerges from the CADTH guidelines is that the best strategy remains gradual tapering of BDZ with little evidence for the use of adjunctive medications. The results show that simple interventions such as discontinuation letters from clinicians, self-help information and support in general, added to gradual tapering may be associated with a two- to three-fold higher chance of successful withdrawal, compared with treatment as usual. We suggest possible implications for day-to-day clinical practice.

Entities:  

Keywords:  Benzodiazepines; discontinuation; effectiveness; guidelines

Mesh:

Substances:

Year:  2016        PMID: 26818890      PMCID: PMC6998737          DOI: 10.1017/S2045796016000032

Source DB:  PubMed          Journal:  Epidemiol Psychiatr Sci        ISSN: 2045-7960            Impact factor:   6.892


  10 in total

1.  The diagnosis and management of benzodiazepine dependence.

Authors:  Heather Ashton
Journal:  Curr Opin Psychiatry       Date:  2005-05       Impact factor: 4.741

2.  Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder.

Authors:  Stephen M Stahl
Journal:  J Clin Psychiatry       Date:  2002-09       Impact factor: 4.384

3.  An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder.

Authors:  David S Baldwin; Christer Allgulander; Borwin Bandelow; Francisco Ferre; Stefano Pallanti
Journal:  World J Biol Psychiatry       Date:  2011-11-07       Impact factor: 4.132

4.  Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project.

Authors:  Consuelo Huerta; Victoria Abbing-Karahagopian; Gema Requena; Belén Oliva; Yolanda Alvarez; Helga Gardarsdottir; Montserrat Miret; Cornelia Schneider; Miguel Gil; Patrick C Souverein; Marie L De Bruin; Jim Slattery; Mark C H De Groot; Ulrik Hesse; Marietta Rottenkolber; Sven Schmiedl; Dolores Montero; Andrew Bate; Ana Ruigomez; Luis Alberto García-Rodríguez; Saga Johansson; Frank de Vries; Raymond G Schlienger; Robert F Reynolds; Olaf H Klungel; Francisco José de Abajo
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-07-07       Impact factor: 2.890

Review 5.  Benzodiazepines revisited--will we ever learn?

Authors:  Malcolm Lader
Journal:  Addiction       Date:  2011-10-17       Impact factor: 6.526

6.  Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.

Authors:  David S Baldwin; Ian M Anderson; David J Nutt; Christer Allgulander; Borwin Bandelow; Johan A den Boer; David M Christmas; Simon Davies; Naomi Fineberg; Nicky Lidbetter; Andrea Malizia; Paul McCrone; Daniel Nabarro; Catherine O'Neill; Jan Scott; Nic van der Wee; Hans-Ulrich Wittchen
Journal:  J Psychopharmacol       Date:  2014-04-08       Impact factor: 4.153

Review 7.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

8.  Benzodiazepine Prescribing in Older Adults in U.S. Ambulatory Clinics and Emergency Departments (2001-10).

Authors:  Erin M Marra; Maryann Mazer-Amirshahi; Gillian Brooks; John van den Anker; Larissa May; Jesse M Pines
Journal:  J Am Geriatr Soc       Date:  2015-09-29       Impact factor: 5.562

Review 9.  Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis.

Authors:  Emanuela Offidani; Jenny Guidi; Elena Tomba; Giovanni Andrea Fava
Journal:  Psychother Psychosom       Date:  2013-09-20       Impact factor: 17.659

Review 10.  A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders.

Authors:  Patricia Berney; Demian Halperin; Rodrigo Tango; Isabelle Daeniker-Dayer; Pierre Schulz
Journal:  Psychopharmacol Bull       Date:  2008
  10 in total
  3 in total

1.  Long-term risk of hip or forearm fractures in older occasional users of benzodiazepines.

Authors:  Hélène Carrier; Sébastien Cortaredona; Viviane Philipps; Hélène Jacqmin-Gadda; Marie Tournier; Hélène Verdoux; Pierre Verger
Journal:  Br J Clin Pharmacol       Date:  2020-05-10       Impact factor: 4.335

2.  Benzodiazepine usage and patient preference for alternative therapies: A descriptive study.

Authors:  Fatema-Tun-Naher Sake; Keith Wong; Delwyn J Bartlett; Bandana Saini
Journal:  Health Sci Rep       Date:  2019-02-21

3.  Surviving Benzodiazepines: A Patient's and Clinician's Perspectives.

Authors:  Carrie M Silvernail; Steven L Wright
Journal:  Adv Ther       Date:  2022-03-03       Impact factor: 4.070

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.